HealthEquity, Inc. (HQY) vs Immunovant, Inc. (IMVT)
A side-by-side comparison of HealthEquity, Inc. and Immunovant, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
HQY
HealthEquity, Inc.
$91.58HealthcareDelayed quote: Oct 6, 2026, 12:40 PM EDT
IMVT
Immunovant, Inc.
$31.98HealthcareDelayed quote: Oct 6, 2026, 12:40 PM EDT
Total return — HQY vs IMVT
growth of $100 · dividends reinvested · last 7yHQY +31.5% (+4.0%/yr)IMVT +234.2% (+18.8%/yr)IMVT compounded faster over this window
HQY IMVT
HQY vs IMVT: by the numbers
- •HQY is the larger company ($7.66B vs $6.60B market cap).
- •HQY is profitable (17.36% net margin) while IMVT runs a net loss (-7585.86%).
Metrics side by side
Valuation
| Metric | HQY | IMVT |
|---|---|---|
| P/E ratio | 33.06 | N/A |
| Forward P/E | 19.39 | N/A |
| PEG ratio | 0.40 | N/A |
| P/S ratio | 5.62 | 930.19 |
| P/B ratio | 3.85 | 8.97 |
| EV / EBITDA | 17.41 | N/A |
| FCF yield | 6.16% | N/A |
Profitability
| Metric | HQY | IMVT |
|---|---|---|
| Gross margin | 75.21% | 0.00% |
| Operating margin | 25.61% | 0.00% |
| Net margin | 17.36% | -7585.86% |
| ROE | 11.88% | -73.19% |
| ROIC | 8.55% | -76.00% |
Growth (annualized)
| Metric | HQY | IMVT |
|---|---|---|
| Revenue CAGR (5Y) | 12.96% | N/A |
| EPS CAGR (5Y) | 83.56% | N/A |
| FCF CAGR (5Y) | 36.72% | N/A |
| Total return CAGR (5Y) | 7.00% | 29.93% |
Frequently asked
- Is HQY or IMVT more profitable?
- HQY runs the higher net margin — HQY at 17.36% versus IMVT at -7585.86%.
- How have HQY and IMVT total returns compared?
- Over the past 5 years, HQY delivered 7.00% and IMVT delivered 29.93% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
HealthEquity P/E ratioHealthEquity ROEImmunovant ROEHealthEquity operating marginImmunovant operating marginHealthEquity revenue growthImmunovant revenue growthHealthEquity free cash flowImmunovant free cash flow
HealthEquity & Immunovant appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.